Perspective Therapeutics Logo
US46489V3024
A40EDR

Perspective Therapeutics

Forecast

The analysts' average price target is €6.84 (+891.30%). The median is €6.84 (+891.30%).

Buy
  9
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Perspective Therapeutics cooperates with Merck on combination study of [212Pb]PSV359 and Keytruda

    Perspective Therapeutics and Merck are conducting a clinical collaboration to evaluate the combination of the alpha‑particle therapy [212Pb]PSV359 and Keytruda (pembrolizumab). The addition is being made in the ongoing Phase‑1/2a trial in patients with FAP‑α‑expressing non‑small cell lung cancer and colorectal cancer; Perspective is the sponsor and Merck is providing pembrolizumab at no cost. The primary objective of the dose‑finding phase is to assess safety and tolerability to establish the recommended Phase‑2 dose; PSV359 is designed to deliver 212Pb selectively to FAP‑α‑positive tumor areas. » More on de.investing.com

Financials

In the last quarter, Perspective Therapeutics had revenue of €17.66K and net profit of -€28.64M

(EUR) September 2026
YoY
Revenue 17.66K 90.09%
Gross profit 17.66K 103.66%
Net profit -28.64M 29.43%
EBITDA -27.45M 28.19%

Fundamentals

Metric Value
Market capitalization
€82.96M
Number of shares
120.76M
52-week high/low
€5.61 - €0.66
Dividends No
Beta
1.99
P/E ratio
-0.61
PEG ratio
-0.04
P/B ratio
0.31
P/S ratio
514.28

Company profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Name
Perspective Therapeutics
CEO
Johan Spoor
Headquarters Seattle, wa
USA
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
11/10/2005
Employees 165
🍪

Parqet  uses cookies. Learn more